azd1390

AZD1390 is an orally bioavailable, ATP‐competitive small molecule inhibitor of ataxia telangiectasia mutated (ATM) kinase, developed primarily for its antineoplastic and radiosensitizing properties. By selectively binding to and inhibiting ATM kinase activity, AZD1390 disrupts ATM-mediated DNA damage response signaling. This inhibition prevents activation of DNA damage checkpoints and impairs repair of double-strand breaks (DSBs), leading to increased tumor cell apoptosis—especially in p53-deficient cells—and enhanced sensitivity to chemo/radiotherapy. Notably, AZD1390 is designed to cross the blood-brain barrier, making it suitable for treating central nervous system tumors such as glioblastoma. The drug has demonstrated manageable safety and preliminary efficacy in combination with radiotherapy in early-phase clinical trials for glioblastoma[1][2][3][4][5][6][7].

Other names

7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one